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Abstract
Background: In Bolivia, in 2008, the under-five mortality rate is 54 per 1000 live births. Diarrhea causes 15% 
of these deaths, and 40% of pediatric diarrhea-related hospitalizations are caused by rotavirus illness (RI). 
Rotavirus vaccination (RV), subsidized by international donors, is expected to reduce morbidity, mortality, 
and economic burden to the Bolivian state. Estimates of illness and economic burden of RI and their 
reduction by RV are essential to the Bolivian state’s policies on RV program financing. The goal of this report 
is to estimate the economic burden of RI and the cost-effectiveness of the RV program. Methods: To assess 
treatment costs incurred by the healthcare system, we abstracted medical records
from 287 inpatients and 6751 outpatients with acute diarrhea between 2005 and 2006 at 5 sentinel hospitals 
in 4 geographic regions. RI prevalence rates were estimated from 4 years of national hospital surveillance. We 
used a decision-analytic model to assess the potential cost-effectiveness of universal RV in Bolivia. Results: 
Our model estimates that, in a 5-year birth cohort, Bolivia will incur over US$3 million in direct medical 
costs due to RI. RV reduces, by at least 60%, outpatient visits, hospitalizations, deaths, and total direct 
medical costs associated with rotavirus diarrhea. Further, RV was cost-savings below a price
of US$3.81 per dose and cost-effective below a price of US$194.10 per dose. Diarrheal mortality and 
hospitalization inputs were the most important drivers of rotavirus vaccine cost-effectiveness. Discussion: 
Our data will guide Bolivia’s funding allocation for RV as international subsidies change.
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. Introduction
Rotavirus is the leading cause of severe gastroenteritis among
hildren under five years of age and is globally responsible for an
stimated 111 million episodes of diarrhea requiring home care,
5 million clinic visits, 2 million hospitalizations, and as many
s 592,000 deaths annually [1,2]. Children in low-income coun-
ries are disproportionately affected by rotavirus, accounting for
ore than 80% of these deaths [1,2]. The introduction of effective
otavirus vaccines is a promising intervention in preventing global
iarrheal morbidity and mortality. However, the high cost of the
ew rotavirus vaccines, compared to relative costs of pennies perdose for older vaccines, has resulted in limited implementation in
low-income countries.
Estimates of the economic burden of rotavirus diarrhea vary
substantially by country [3–30]. For example, adjusting by popula-
tion, the annual per capita costs for treatment of rotavirus diarrhea
ranged from US$0.07 per person in the Dominican Republic [7]
to over US$0.97 per person in the United States [13]. Therefore,
country-specific rotavirus cost-burden estimates are essential to
assess the country-specific cost effectiveness of the rotavirus vac-
cine. Cost-effectiveness analysis (CEA) outcome measures permit
standardized comparisons of cost-effectiveness across a range of
health interventions. The results of published CEAs for rotavirus
vaccination have varied. Out of 36 published studies, universal
rotavirus vaccination was determined to be potentially cost sav-
ing in three studies [31–33], potentially cost-effective in 27 studies
[3,4,6,13,29,30,32,34–52], unlikely to be cost-effective in six stud-
ies [53–58], and inconclusive in one study [59]. Estimates of costs
per DALY averted ranged from US$15.32 in middle-income Asian
countries (vaccine price of US$2 per course) [6] to US$10,656 in
Table 1
Variables used in the cost-effectiveness and impact analyses.
Variable Reference(s) for
baseline estimate
Baseline estimate
(range)
Distribution for
uncertainty analysis a
Health
Birth cohort [64] 251,000 NA
Percent of <5 deaths due to diarrheal disease [62] 0.15 NA
Diarrheal mortality rate/1000 live births [62] 0.0081
(0.0073–0.0089)
±10% [34]
Health care
Hospitalization rate of acute diarrheal disease (<5 years of age) in
Birth cohort
[65] 0.94 (0.07–0.12) ±30%
Hospitalization length of stay Study data 5 NA
Outpatient visit rate for acute diarrheal disease (<5 years of age) in
Birth cohort
[65] 0.76 (0.53–0.99) ±30%
Proportion of hospitalized diarrhea cases with rotavirus b 0.40 NA
Proportion of outpatient diarrhea cases with rotavirus b 0.25 NA
Proportion of diarrhea deaths due to rotavirus c 0.40 NA
Vaccine efficacy
Against severe rotavirus resulting in death [72] 0.85 (0.51–0.871) ±2.5 [79], −40% [80]
Against severe rotavirus resulting in hospitalization [72] 0.85 (0.51–0.897) +5.5% [79], −40% [80]
Against rotavirus resulting in an outpatient visit [50,72] 0.78d
(0.468–0.823)
+5.5% [79], −40% [80]
DPT coverage [71] 0.44–0.88
(0.33–0.66–0.55–1.0)
±25% [37]
Cost data
Outpatient costs Study data 16.88
(12.39–20.65)
±25% [4,6,37,50]
Inpatient costs Study data 260.57
(193.85–323.08)
±25% [4,6,37,50]
Cost of administration [4,34,37,44,51,73] 0.50 NA
a NA: not applicable, not included in one-way or multivariate models.
b Local surveillance data from Bolivia’s National Rotavirus Surveillance Program.
c No reliable data exists so range assumed it equal to the equivalent hospitalized data.
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d Vaccine efficacy against cases requiring outpatient care was estimated to be the
everity (70%) [50].
hile (vaccine price of US$24 per course) [7]. The break-even price
f the vaccine, defined as the price at which vaccination costs equal
he costs saved by the health system, ranged from US$0.18 in low-
ncome Asian countries [6] to US$54 USD in Taiwan [57].
While many Latin American countries have undertaken cost-
ffectiveness analyses to facilitate policy decisions regarding
otavirus vaccination, Bolivia remains an exception. Bolivia is one
f the least developed countries in the Americas, with nearly 60%
f the population living in conditions of poverty and nearly 25% liv-
ng in conditions of extreme poverty [60]. The nation suffers from
he region’s highest rates of childhood mortality, and the World
ealth Organization (WHO) estimates that diarrhea is responsible
or 15% of these deaths [61]. In 2008, Bolivia implemented a univer-
al rotavirus vaccination campaign with financial support from The
lobal Alliance for Vaccines and Immunization (GAVI) through the
ear 2017. The goal of this paper is to fill gaps in knowledge regard-
ng the economic burden of rotavirus and cost-effectiveness of the
otavirus vaccination program in Bolivia. The subsequent analysis
rovides data for decision makers regarding the projected eco-
omic impact of vaccination at a range of vaccine prices reflecting
he dynamic market value of this vaccine.
. Methods
.1. Model
To calculate the cost-effectiveness of universal rotavirus vacci-
ation in Bolivia, data were analyzed through an economic model
eveloped by Rheingans et al. [44,51]. This decision model was
reated using Microsoft 2000 Excel software (Microsoft Corpora-
ion, Redmond, Washington) and compares the cost of universal
otavirus vaccination in Bolivia (intervention costs) with the
ypothetical treatment costs of rotavirus diarrhea potentiallyge of the efficacy against severe rotavirus illness (85%) and rotavirus illness of any
prevented by vaccination. Model inputs included country-specific
economic, health systems, demographic and rotavirus epidemiol-
ogy data, encompassing rotavirus disease morbidity and mortality,
healthcare utilization and costs for rotavirus-associated events,
and vaccination coverage (Table 1). The model examined cost-
effectiveness from a health system point-of-view, and no data
regarding societal costs borne by individuals (e.g. costs to fill pre-
scriptions, work days lost, etc.) were included.
2.2. Rotavirus morbidity and mortality
Diarrheal mortality in children under 5 years of age and an
estimate of annual diarrheal deaths in Bolivia was calculated
using 2010 mortality rates from the World Health Organization
(WHO) [62]. We assumed the proportion of diarrhea deaths due
to rotavirus was the same as the proportion of hospitalized cases
due to rotavirus, as etiological data was not available for diarrhea
mortality. We estimated the five-year cumulative risk for hospi-
talization and outpatient care due to rotavirus disease based on
administrative data from the National Statistics Institute of Bolivia
[63], the 2003 birth cohort (251,000 consistent through 2009) [64],
and data on the proportion of these events due to rotavirus, as
identified by the National Rotavirus Surveillance Program (NRSP)
in Bolivia (Table 1).
The rates of hospitalization and outpatient care for diarrheal
diseases were calculated by dividing the annual number of hospi-
talizations and outpatient visits due to diarrhea (National Statistics
Institute in Bolivia [65]) by the birth cohort (251,000) [64]. The
proportion of hospitalized children with rotavirus diarrhea was
obtained from data from Bolivia’s National Rotavirus Surveillance
Network. Within surveillance hospitals, rotavirus diarrhea was
defined as a child whose inpatient stool tested positive for rotavirus
with the OXOID ProSpecTTM Rotavirus EIA Kit test (Oxoid, United
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ingdom). The average length of stay for children treated for
otavirus in each type of facility was calculated from patient data
ollected as part of this study. A summary of the baseline inputs for
he model is in Table 1.
.3. Study population
Data collection on treatment costs took place at five sen-
inel hospitals (Hospital Boliviano Holandes in El Alto, Hospital
aterno Infantil and Hospital del Nino in La Paz, Centro Pedi-
tria Albino R. Patiño in Cochabamba, and Hospital Mario Ortiz
uarez in Santa Cruz) participating in Bolivia’s rotavirus surveil-
ance program. These sites included both privately and publicly
unded hospitals, and pediatric and general hospitals. Data was
bstracted from inpatient and emergency department records of
hildren less than 60 months of age treated for acute diarrheal
isease.
The inpatient study population included a total of 287 patients
dmitted to the hospital for at least one night with diarrheal disease
etween August 1st, 2005 and August 30th, 2006. WHO guidelines
or selecting an appropriate sample size suggest selection of every
fth patient with a diagnosis of acute diarrhea [66], however, we
elected every third inpatient to ensure an adequate sample size.
he outpatient study population included all 6751 patients who
resented to the emergency departments of surveillance hospitals
ith acute diarrhea between January 1, 2006 and December 31,
006. Outpatient records with missing data regarding treatment or
iagnostics were removed from the database to avoid underesti-
ation of direct medical costs. Exclusion criteria included age over
0 months, dysentery, or a note of suspected bacterial, parasitic,
ietary or other non-viral cause of diarrhea. Patients with a co-
orbidity of pneumonia were also excluded to avoid the inclusion
f costs not related to diarrhea treatment.
.4. Cost data
Cost data was estimated from medical records data and previ-
usly published estimates. Only direct medical costs were included
n the calculations of cost data.
.4.1. Inpatient costs
We found a wide variation in hospital bed-day cost data both
etween hospitals and among patients at the same hospital based
n insurance coverage. Despite protracted research and interviews
ith the hospitals accounting department and Ministry officials, we
ould not guarantee that hospital bed-day costs excluded govern-
ent subsidies or used consistent pricing methodology. Therefore,
or consistency across facilities and reliability of the price of a hos-
ital bed-day to the state, we used WHO 2005 country-specific
stimates of unit-costs for these patient services [67]. All hospi-
als in the study fit the WHO’s definition of a tertiary hospital [68];
herefore, tertiary-level cost estimates were used for all inpatients
nd outpatients who received care in a hospital setting. These esti-
ates account for costs such as personnel, capital, and food, but
xclude diagnostics and medications.
Medications, medical equipment, and diagnostic tests ordered
or inpatients were abstracted from pharmacy records and patient
harts. Drug and medical equipment costs were estimated from
anagement Sciences for Health’s (MSH) International Drug Price
ndicator Guide [69] or the International Dispensary Associa-
ion’s (IDA) catalogue [70]. If a medication was not listed in
ither of these sources, Bolivia’s government health insurance
eimbursement rate for the given medication was used. Diagnos-
ic costs were not available from either MSH or IDA; therefore
olivia’s government health insurance reimbursement rate was
sed. Costs for which data was available in Bolivianos (BOB) wereconverted into USD using the 2008 exchange rate of 1 BOB equal to
US$0.125.
Bolivia’s health care system follows a three-tiered standardized
guide for treating diarrhea according to the severity of dehydra-
tion: Plan A for mild dehydration, Plan B for moderate dehydration,
and Plan C for severe dehydration. Plans A and B can be adminis-
tered orally over the course of several hours and Plan C is designed
to be administered intravenously over 2 days of inpatient care.
Three assumptions were made to estimate treatment and diagnos-
tics costs: (1) if a specific Plan was indicated in patient records, all
specified components of the Plan were used plus any additional
recorded medicines or diagnostics. (2) If no Plan was indicated,
but any individual components of intravenous rehydration were
recorded, then it was assumed that 1 Plan C package was admin-
istered for every 2 days of inpatient treatment. (3) If no Plan or
intravenous rehydration was indicated, but specific medications
were indicated (5% of records), only those indicated medications
were used to calculate cost of treatment.
2.4.2. Hospital outpatient costs
No outpatient visit cost estimates for treatment in a hospital
emergency department were available from surveillance facilities;
therefore WHO-CHOICE cost estimates for this type of visit were
used. Medications, IV rehydration components, medical equip-
ment, and diagnostics ordered for each patient were abstracted
using the methods described above. If Plan C was indicated in the
records, it was assumed that the cost for an entire Plan C package
was incurred. This is due to the fact that a full Plan C package can-
not be administered in one day; however, the package components
cannot be administered for a second patient and must be discarded
if a second day of treatment is not completed.
2.4.3. Outpatient treatment in a non-hospital setting
Because we did not collect data from outpatient treatments of a
diarrheal episode in non-hospital settings, we assumed that outpa-
tient treatments in these settings was limited to Plan A. Therefore,
we estimated the cost of treatment in this setting as the cost of a
Plan A package plus the WHO-CHOICE estimate of an outpatient
visit cost in a non-hospital setting [67].
2.5. Vaccine characteristics
National coverage of Diphtheria, Pertussis and Tetanus (DPT)
vaccine was used as a proxy for the potential coverage of rotavirus
vaccination because the recommended schedule is the same for
both vaccines. Data on DPT 1 and 2 vaccination coverage and tim-
ing was calculated from the 2003 Bolivia Demographic and Health
Survey [71]. Vaccine efficacy was estimated to be 85% against both
deaths and hospitalizations due to rotavirus [72]. Because children
who are at higher risk for rotavirus mortality are also less likely
to receive rotavirus vaccine immunization, the model incorporates
a relative coverage correction factor for vaccine efficacy against
death. We assumed that vaccine coverage of those most likely to die
from rotavirus was 90% of the vaccine coverage of the remainder
of the population. Vaccine efficacy against cases requiring outpa-
tient care was estimated to be the average of the efficacy against
severe rotavirus illness (85%) and rotavirus illness of any sever-
ity (70%) [51,72]. Based on other studies [4,34,37,44,51,73] and
confirmed by the Ministry of Health and Sports and the National
Rotavirus Surveillance Program, administration costs per dose of
vaccine were assumed to be US$0.50.2.6. Cost-effectiveness analysis
The primary measurement of cost-effectiveness for this study
was the incremental cost-effectiveness ratio (ICER) per DALY
Table 2
Hospitalized and outpatient cases of diarrhea.
El Alto La Paza Cochabamba Santa Cruz Bolivia total
Hospital
% RV positive cases (n) 39.6 (48) 41.1 (90) 42.9 (63) 31.4 (54) 39.2 (255)
Mean months ± SEM (n) 12.7 ± 1.24 (48) 12.7 ± 0.96 (92) 12.2 ± 1.01 (60) 13.1 ± 1.6 (18) 12.6 ± 0.6 (218)
Percent male (n) 69.5 (46) 55.5 (90) 47.8 (69) 58.6 (46) 56.5 (251)
Mean length of stay in days (n) 6.3 (53) 4.7b (100) 4.5b (78) 4.6b (55) 4.9 (286)
Outpatient
Mean months ± SEM (n) 14.8 ± 0.3 (898) 14.8 ± 0.3 (1082) 12.5 ± 2.1 (17) 15.1 ± 0.1 (2955) 15.0 ± 0.1 (4952)
Percent male (n) 55.7 (896) 55.5 (1083) 56.5 (1120) 55.2 (2952) 55.6 (6051)
a Cost data were collected at two hospitals for inpatients and one hospital for outpatients in La Paz.
b p < 0.05 compared to El Alto.
Table 3
Average healthcare costs paid by Bolivian healthcare facilities per hospitalized or emergency department patient, stratified by surveillance city.
Mean ± SEM (n) El Alto La Paza Cochabamba Santa Cruz Bolivia average
Hospital
Total bed-day $279.99 ± 27.54 (53) $210.15b ± 11.86 (100) $201.64b ± 13.91 (78) $205.19b ± 13.86 (55) $219.82 ± 8.21 (286)
Medicines $39.18 ± 3.44 (53) $29.21b ± 1.46 (100) $29.44b ± 1.74 (78) $31.59 ± 1.76 (55) $31.57 ± 1.03 (286)
Diagnostics $10.11 ± 0.79 (53) $7.38c ± 0.62 (100) $12.06 ± 0.77 (78) $7.44c ± 0.81 (55) $9.17 ± 0.39 (286)
Total $329.28 ± 30.98 (53) $246.74b ± 13.31 (100) $243.14b ± 15.59 (78) $244.22b ± 15.62 (55) $260.57 ± 9.25 (286)
Outpatient
Total $16.75c ± 0.05 (901) $16.59c ± 0.02 (1085) $17.44 ± 0.07 (1134) $16.80c ± 0.03 (2960) $16.88 ± 0.02 (6080)
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a Data for hospitalized costs were collected at two hospitals in La Paz and one ho
b p < 0.05 compared to El Alto.
c p < 0.05 compared to Cochabamba.
verted. A 3% discount rate was utilized for all costs and outcomes.
he ICER was calculated using a range of vaccine price between
S$3 and US$24 per dose. Additional outcome variables calculated
nclude the cost per death averted, the break-even price, and esti-
ates of rotavirus-related events and medical costs averted by
accination. WHO-CHOICE thresholds are used to define a health
ntervention as very cost-effective if the cost per DALY averted
s less than the GDP per capita of the nation implementing that
ntervention [67].
.7. Sensitivity analysis
To assess the combined impact of uncertainty in the input
arameters, we conducted a Monte Carlo simulation using Crys-
al Ball version 11.1.2.1.0 (Oracle, CA). Input ranges were defined
or each key input parameter based on ranges in published data
Table 1). The Monte Carlo procedure selects one value from each
nput distribution and is repeated with 10,000 iterations to con-
truct a distribution of likely outputs. A one-way sensitivity analysis
ith the same input ranges was also conducted to assess the mag-
itude of impact of each variable on projected cost-effectiveness
tilizing the current vaccine price per dose for Bolivia (US$9.00)..8. Ethical considerations
All portions of the study, including inpatient and outpa-
ient chart abstraction, were approved by Emory University’s
able 4
rojected impact of vaccination: estimated rotavirus-related events in the 2003 birth coh
Events without vaccination Events with
Outpatient visits 47,560 18,103
Hospitalizations 9482 3082
Deaths 813 317
DALYs 27,753 10,841
Outpatient direct medical costs $589,431 $224,466
Hospitalization direct medical costs $2,421,400 $787,561
Total direct medical costs $3,010,831 $1,012,027
a 95% CL were estimated from a multivariate sensitivity model described in Section 2.for outpatients.
Institutional Review Board (Protocol IRB00004406) and the Boli-
vian National Bioethics Committee prior to data collection.
3. Results
3.1. Study population and economic burden of rotavirus to
Bolivia’s health care system
Among hospitalized children in our study population, about 40%
of patients tested positive for rotavirus infection (Table 2). The
average length of hospitalization was 4.9 days. The percentage of
rotavirus positive cases was not significantly different between
cities with sentinel hospitals. On average, children in El Alto had
significantly longer hospital stays than those in other cities. The
mean age for children in our study population was 12.6 months
among inpatients and 15 months among outpatients.
In Bolivia, the average total cost for hospitalization was
US$260.57 and the average total cost for an outpatient event was
US$16.88 (Table 3). Generally, the total cost per hospitalization was
composed of bed day costs (84%), medicines (12%), and diagnostics
(4%). Patients in El Alto incurred significantly higher total bed-day
and medication costs, likely due to the significantly longer average
length of stay in comparison to other sites. Cochabamba patients
had significantly higher diagnostic costs compared to La Paz and
Santa Cruz, likely because it was the only private hospital sampled,
and public hospitals run diagnostic tests for diarrhea cases with
less frequency. Outpatient costs per patient were similar across
ort with and without vaccination.
vaccination Averted by vaccine [95% CL]a % reduction
29,457 [24,455–31,320] 62
6400 [5271–8534] 67
496 [424–658] 61
16,912 [12,698–19,866] 61
$364,965 [$279,613–$427,084] 62
$1,633,839 [$1,123,760–$2,056,853] 67
$1,998,804 [$1,471,226–$2,435,146] 66
Table 5
Estimated costs and cost-effectiveness of universal rotavirus vaccination in the 2003 birth cohort.
Vaccination cost Cost per DALY averted [95% CL]b Cost per death averted [95% CL]b
At $3/dose $1,619,170.88 CS [CS–$9.20] CS [CS–$312.24]
At $4/dose $2,087,878.24 $5.27 [CS–$39.40] $179.71 [CS–$1345.51]
At $5/dose $2,556,585.60 $32.98 [$8.70–$70.40] $1125.36 [$296.24–$2403.97]
At $9/dosea $4,431,415.04 $143.84 [$115.10–$206.50] $4907.93 [$3927.13–$7051.76]
At $10/dose $4,900,122.40 $171.56 [$140.10–$242.30] $5853.57 [$4779.57–$8271.05]
At $15/dose $7,243,659.20 $310.13 [$262.27–$421.53] $10,581.78 [$8943.98–$14,394.06]
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rotavirus and cost-effectiveness of the rotavirus vaccination pro-
gram in Bolivia for use in policy development as subsidization of
universal rotavirus vaccination is withdrawn in 2017. We estimate
the annual economic burden of rotavirus at over US$3 million. We
Table 6
Sensitivity analysis (at $9.00/dosea).
Variable Input value % changeb ICERc % change
Diarrheal mortality rate
0.010 +20 119.92 −17
0.008 Baseline 143.84 0
0.006 −20 179.68 +25
Diarrheal hospitalization rate
0.12 +30 114.86 −20.1
0.0945 Baseline 143.84 0
0.07 −30 172.82 +20.1
Diarrheal outpatient rate
0.99 +30 137.36 −4.5
0.7581 Baseline 143.84 0
0.53 −30 150.32 +4.5
Hospitalization costsa
325.71 +25 119.69 −17
260.57 Baseline 143.84 0
195.43 −25 167.99 +17
Outpatient costsa
21.10 +25 138.45 −4
16.88 Baseline 143.84 0
12.66 −25 149.24 +4
Vaccine efficacy against death
0.871 +2.5 140.34 −2.4
0.85 Baseline 143.84 0
0.51 −40 239.31 +66.4
Vaccine efficacy against hospitalizations
0.897 +5.5 138.53 −3.7
0.85 Baseline 143.84 0
0.51 −40 182.49 +26.9
Vaccine efficacy against outpatient visits
0.823 +5.5 142.65 −0.8
0.780 Baseline 143.84 0At $20/dose $9,587,196.00 $448.7
a Price in Bolivia as of July 2010 is $9.08.
b 95% CL were estimated from a multivariate sensitivity model described in Secti
ll facilities, although Cochabamba had slightly significantly higher
utpatient costs compared to other cities.
.2. Estimated impact of rotavirus vaccination on the economic
urden of rotavirus to Bolivia’s health care system
In the absence of vaccination, we estimated that the birth cohort
ould experience 47,560 outpatient visits, 9482 hospitalizations,
nd 813 deaths before reaching age 5, accounting for 27,753 DALYs
Table 4). As a result of rotavirus related diarrhea, 189 out of every
000 children will have received outpatient treatment, 38 out of
very 1000 children will have been hospitalized, and 3 out of every
000 children will die by age 5. From these data, we estimated
rotavirus-associated economic burden of US$3,010,831 per year
rom the healthcare perspective (Table 4). In other words, US$12.00
n direct medical costs will be spent for every child in the cohort.
hough the number of outpatient events was about five times
igher than hospitalization events, the majority (80%) of Bolivia’s
conomic burden was attributable to events requiring hospitaliza-
ion.
We estimated that universal rotavirus vaccination, with an esti-
ated coverage based on current national DPT coverage, would
educe outpatient and hospitalization visits, deaths, and DALYs by
ver 60%. In general, the percentage of events averted increases
ith vaccination coverage. Notably, we estimated that rotavirus
accination would reduce annual direct medical costs for rotavirus-
ssociated events by 66%, from US$3,010,831 to US$1,012,027.
.3. Cost effectiveness of rotavirus vaccination
International financial subsidies for Bolivia’s rotavirus vaccina-
ion program do not provide a sustainable strategy for a permanent
otavirus vaccine program. Bolivia has agreed to contribute 40% of
accine costs during the first five years of vaccine rollout, eventu-
lly moving towards total government financing of the program
y 2017 [74]. Given the uncertainty of future vaccination costs,
e modeled cost-effectiveness across a plausible range of prices
Table 5). The medical break-even price was calculated at US$7.62
er vaccine course (2 doses). According to WHO standards for
ost-effectiveness, an intervention is very cost-effective if the ICER
s less than the GDP per capita and cost effective if the ICER is
ess than three times a nation’s GDP per capita. Utilizing Bolivia’s
DP (US$1758 [75]) as a threshold, rotavirus vaccination is very
ost-effective for Bolivia up to a price of US$67.24 per dose and
ost-effective up to a price of US$194.10 per dose. Using cost per
eath averted as a measure of cost-effectiveness, rotavirus vacci-
ation would be very cost-effective up to US$5.66 per dose and
ost-effective up to US$9.38 per dose..4. Sensitivity and uncertainty analysis
To assess which inputs were the most important drivers of cost-
ffectiveness at Bolivia’s current price per dose (US$9.00), we varied81.76–$601.34] $15,310.00 [$13,020.99–$20,533.80]
S: cost savings.
each individual model input in both one-way (Table 6) and prob-
abilistic multivariate sensitivity (Tables 4–5) analyses. None of the
input variations for the sensitivity analysis resulted in cost-savings
at the current price of US$9.00 per dose. In general, ICERs were
more affected by variations in the diarrheal mortality (rate of mor-
tality, vaccine efficacy against death) and hospitalization inputs
(diarrheal hospitalization rate, hospitalization costs, and vaccine
efficacy against hospitalizations) than outpatient inputs (Table 6).
Similarly, costs per DALY averted were most sensitive to changes
in diarrheal mortality followed by hospitalization inputs, and less
sensitive to changes in outpatient inputs (data not shown).
4. Discussion
The goal of this report was to estimate the economic burden of0.468 −40 152.50 +6
a Price in Bolivia as of July 2010 is $9.08.
b Costs were varied by each event/input costs/rate/efficacy as per ranges specified
in Table 1.
c Cost-effectiveness ratio defined as cost per DALY averted (US$/DALY).
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Table 7
Comparison of cost-effectiveness ratios of various childhood health interventions to
prevent diarrhea mortality for high-mortality nations in the WHO Americas region.
Intervention ICERa Source
Rotavirus vaccination in Bolivia
At $3/dose CS This study
At $4/dose $5.27 This study
At $5/dose $32.98 This study
At $9/dose $143.84 This study
At $10/dose $171.56 This study
Oral rehydration therapy expansion to 80% $249.00 [67]
Oral rehydration therapy expansion to 95% $289.00 [67]
Vitamin A supplementation expansion to 50% $209.00 [67]
Vitamin A supplementation expansion to 80% $393.00 [67]
Zinc supplementation expansion to 50% $43.00 [67]
Zinc supplementation expansion to 80% $40.00 [67]
a Cost-effectiveness ratio defined as cost per DALY averted (US$/DALY). 95% CLound that rotavirus vaccination reduces, by at least 60%, the num-
er of outpatient visits, hospitalizations, deaths, DALY’s, and total
irect medical costs associated with rotavirus diarrhea. Further, the
otavirus vaccine was cost-savings below a price of US$3.81 per
ose and cost-effective at Bolivia’s current price of $9 per dose.
The reduction in rotavirus related events and direct medical
osts averted are concordant with previously published stud-
es in other lower-middle and upper-middle-income countries
6,29,36,50,51,76]. Our estimation of hospitalization costs per
atient (Table 3) is generally higher than published estimates from
ountries of similar economic status based on GDP per capita,
ncluding Vietnam [4], Indonesia [73], and Kyrgyzstan [37]. Our
stimate was most similar to published estimates of hospitaliza-
ion costs in Peru ($284.08) [36] and Malaysia ($187.72) [20], both
f which have a higher economic status than Bolivia. As expected,
ospitalizations exhibited a larger reduction in events (Table 4) and
osts (data not shown) than outpatient visits due to the rotavirus
accine. This is likely due to greater vaccine efficacy against hos-
italizations than against diarrheal episodes requiring outpatient
reatment (Table 1) and higher hospitalization costs than outpa-
ient visit costs (Table 3).
The estimated break-even price was higher than estimates for
ountries of similar economic status [51,73], and more similar to
he break-even price calculated for some upper-middle-income
ounties including Chile (US$10.33 per course [51]) and Panama
US$7.56 per course [51]). The ICERs for rotavirus vaccination in
olivia (US$143.84 per DALY averted at US$18 per vaccine course)
ere comparable to ICERs from analyses for countries of similar
conomic status including Indonesia ($US120.46/DALY averted at
S$14/course) [73] and low-income Asian countries (US$212/DALY
verted at $20/course) [6].
If Bolivia were to commit the sum of its current government
accine expenditures (US$8,294,595 for 2009 [64]) to universal
otavirus vaccination, it could only afford to purchase the rotavirus
accine below a price of US$17.24 per dose (data not shown).
hough our model demonstrates cost-effectiveness for even higher
rices, this situation is not pragmatic given the numerous essen-
ial childhood vaccines that must be considered in the national
udget. After the first five years of vaccine rollout subsidized by
AVI, Bolivia will have to allocate a higher percentage of its health
ystems budget to rotavirus vaccination and re-negotiate rotavirus
accine prices. Based on our analyses, regardless of the final price
olivia obtains for rotavirus vaccine, universal vaccination will
robably remain a highly cost-effective health intervention. It is
mportant to note that rotavirus vaccination in Bolivia, at the cur-
ent price of $9/dose, is comparatively more cost-effective than
ther most other early childhood health interventions such as
xpansion of oral rehydration therapy or vitamin A supplemen-
ation programs (Table 7). It should also be noted that as vaccine
roduction expands with accelerated introduction into other coun-
ries, the price per dose and cost per DALY averter are likely to
ecrease and cost-effectiveness ratios will improve [34].
Any results of cost-effectiveness analyses are highly dependent
n input data variability [78]. For this reason, sensitivity analy-
es are crucial to addressing the uncertainty of input parameters.
hile economic analyses of other developing countries also found
ost-effectiveness to be most sensitive to mortality and vaccine
fficacy inputs [4,6,41,44,45,50,51], it is interesting to note that
ospitalization rate and costs are typically more important drivers
f cost-effectiveness in countries of higher socioeconomic status
han Bolivia [6] due to the higher costs associated with hospi-
alizations in these countries. It is possible that hospitalization
nputs were significant drivers of cost-effectiveness in our study
ecause our estimated costs per hospitalization (US$260.57) were
ore similar to costs in higher-income countries than Bolivia. How-
ver, our base rates of vaccine efficacy are consistent with previouswere estimated from a multivariate sensitivity model described in Section 2. CS:
cost savings.
studies using similar methodology [4,6,29,37,50,51] and the 95%
CL for all the outputs include recent real-world effectiveness stud-
ies conducted in high-mortality settings [79,80]. In addition, the
range of the estimated percentage of deaths due to diarrhea among
under 5 deaths in Bolivia from various sources is 30%: estimates
from WHO and PAHO include 7% [81], 15% (used in this model
[61]), and 37% [82]. The variation is exacerbated because we have
poor estimates for rotavirus-specific mortality. In this study, we
utilize the rotavirus-specific hospitalization rate (40%) as a proxy
for the rotavirus-specific mortality rate; however, of a small sample
of children with acute diarrheal disease who died while receiving
treatment in Bolivian surveillance hospitals, 70% were rotavirus
positive (communication with Surveillance program staff). Isak-
baeva et al. faced an even more difficult challenge in Uzbekistan
where there was a 106% variation in rotavirus diarrhea mortality
rates depending on the data source [30]. In summary, the sensitiv-
ity analysis does not completely capture the possible variation in
reported diarrhea mortality in Bolivia.
The main strength of this study lies in the accuracy and valid-
ity of the model inputs. For example, we used values for the
proportion of pediatric diarrhea hospitalizations due to rotavirus
(gleaned from 4 years of national rotavirus sentinel hospital surveil-
lance across multiple geographic regions), direct medical costs
(multi-year data collection from all the sentinel hospitals and
WHO-CHOICE data) and vaccine efficacy rates (from RotarixTM
clinical trials). To achieve robust cost data, we oversampled both
inpatient and outpatient study populations. A second strength was
our ability to compare cost data collected through vigorous in-
country data abstraction to data available from easily accessible
data sources such as WHO-CHOICE. We determined that bed-day
costs provided by hospital administration departments were not an
accurate reflection of true costs, and therefore WHO-CHOICE was
a more reliable cost input (Section 2). Therefore, we examined a
range of possible costs in our sensitivity analysis (Table 1) in order
to incorporate what was likely the true hospitalization cost.
Our main limitation was that our analyses did not include data
on societal costs borne by families of children with rotavirus.
One reason for excluding these costs from this analysis was that
these costs are not usually an important driver in economic
decision-making by the government. However, studies that have
included these data along with health care system costs often
estimate a higher level of cost-effectiveness [78]. A second limi-
tation is that our study did not incorporate other variables into
the cost-effectiveness estimate such as changing recommended age
restrictions for rotavirus vaccine administration [83], possible risk
of intussusception in certain populations [83], and possible obsta-
cles to rotavirus vaccine efficacy including: varied host protection
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ith incomplete doses [84,85] and the effect of host nutritional
tatus [86–88]. A third limitation is that our estimations of health
are costs and utilization based on the tertiary-level hospitals in
he National Rotavirus Surveillance Program likely contributed to
igher estimations of costs and cost-effectiveness because more
evere cases of diarrhea may present at tertiary hospitals than pri-
ary or secondary health facilities. In exchange for this limitation,
e were able to directly estimate the proportion of laboratory con-
rmed rotavirus hospitalization and outpatient diarrhea cases and
apture a wide range of variation in utilization and costs in Bolivia
ased on geographic and climatic region and socioeconomic level
f the population served.
In conclusion, we found that incorporating rotavirus vaccination
n Bolivia’s immunization program is a cost-effective intervention
o decrease under-five mortality and morbidity and reduce med-
cal expenditures to the health system. Our model demonstrated
hat universal rotavirus vaccination averted over 60% of rotavirus
elated health outcomes and costs and was cost-effective at the
urrent price of $9 per dose. However, it is important to practically
ssess Bolivia’s ability to fund universal vaccination as interna-
ional subsidies are gradually withdrawn over the next five years.
ur analyses will help guide Bolivia’s decision making process as it
onsiders its future allocations for childhood vaccine programs.
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